PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX , with Top-Line Results Anticipated in Current Quarter Com

PolyPid Provides Corporate Update and Reports

First Quarter 2025 Financial Results

PolyPid Successfully

Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX , with Top-Line Results Anticipated in Current Quarter

Company Continues to

Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions

Conference Call Scheduled for Today at 8:30

PETACH TIKVA, Israel, May

14, 2025 -- PolyPid Ltd. (Nasdaq: PYPD)

("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided

a corporate update and reported financial results for the three months ended March 31, 2025.

Recent Corporate Highlights:

track for a transformational year in 2025. We continue to view the SHIELD II Phase 3 trial as a derisked study. This assessment has been

further strengthened by the 800-patient sample size reassessment which helps ensure the study has

sufficient power to conclusively confirm D-PLEX100's treatment benefit and we believe this increases the trial's overall

probability of success", stated Dikla Czaczkes Akselbrad, PolyPid's Chief Executive Officer. "As we await the

top-line results from SHIELD II later this quarter, we continue to advance our preparations for NDA and MAA submissions in 2026. Moreover,

we continue to progress our commercial plans, as well as engage in partnership discussions with

multiple potential partners in the United States."

Financial results for three months ended March

Balance Sheet Highlights

Conference Call Dial-In & Webcast Information:

site Hospital acquired Infection prEvention with Local D-PLEX) is a prospective, multinational, randomized, double blind Phase 3 trial

designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with standard of care ("SoC"),

which includes prophylactic systemic antibiotics, compared to SoC alone arm, in the prevention of post abdominal-surgery incisional infection

in patients undergoing abdominal colorectal surgeries with large incisions. The primary endpoint of the trial is measured by the proportion

of subjects with either a surgical site infection ("SSI") event as determined by a blinded and independent adjudication committee,

reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. The

trial will enroll patients in centers in the United States, Europe and Israel.

D-PLEX100, PolyPid's

lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to

prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation

matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic

doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential

to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 received Breakthrough Therapy

Designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal

surgery. D-PLEX100 is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients

undergoing abdominal colorectal surgery with large incisions.

is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics,

PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs),

enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product

candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.

In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning

For additional Company information, please

visit http://www.polypid.com and

Forward-looking Statements

This press release contains "forward-looking

statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects,"

"anticipates," "intends," "plans," "believes," "seeks," "estimates"

and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using

forward-looking statements when it discusses the potential efficacy and benefits of D-PLEX100 and the probability of success

of the trial, that the current cash balance will be sufficient to fund the operations into the third quarter of 2025, the expected timing

for completion of enrollment of the SHIELD II trial, the expected timing for top-line results from the SHIELD II trial, potential NDA

and MAA submissions and the timing thereof, finalization of CMC and non-clinical modules,

potential clinical benefits of D-PLEX100, the potential to receive up to an additional $27.0 million from the exercise of the

warrants from the recent financing, Company's anticipation that with such additional funding,

PolyPid's runway would be extended beyond anticipated NDA approval, and the Company's potential strategic partnerships.

Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections,

many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However,

there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ

materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and

uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements.

For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports

filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company's

Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made.

The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances,

changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities

laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional

updates with respect thereto or with respect to other forward-looking statements.

References and links to websites have been

provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is

not responsible for the contents of third-party websites.

INTERIM CONDENSED CONSOLIDATED

U.S. dollars in thousands

INTERIM CONDENSED CONSOLIDATED

U.S. dollars in thousands (except share and

INTERIM CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share and